Losartan and diabetic nephropathy: commentaries on the RENAAL study

Losartan and diabetic nephropathy: commentaries on the RENAAL study

<p>Abstract</p> <p>The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study is a multinational, double-blind, randomized, placebo controlled trial which was recently published. It was aimed to evaluate the effect of the angiotensin receptor blo...

Full description

Bibliographic Details
Main Authors:	Tenenbaum Alexander, Fisman Enrique Z, Motro Michael
Format:	Article
Language:	English
Published:	BMC 2002-04-01
Series:	Cardiovascular Diabetology
Subjects:	Angiotensin receptor blockers Clinical trials Diabetes mellitus Losartan Nephropathy RENAAL study
Online Access:	http://www.cardiab.com/content/1/1/2

Similar Items

The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland - an analysis of the RENAAL study
by: MS Sandoz, et al.
Published: (2004-08-01)

A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19
by: Michael A. Puskarich, et al.
Published: (2021-07-01)

A randomised clinical trial study assessing the efficacy of 5% losartan potassium loaded in ethosomal gel to treat human keloids: a trial protocol
by: Yuni Eka Anggraini, et al.
Published: (2024-01-01)

Losartan for Preventing Aortic Root Dilatation in Patients with Marfan Syndrome: A Meta-Analysis of Randomized Trials
by: Ayman Elbadawi, et al.
Published: (2019-10-01)

Losartan Alleviates the Side Effects and Maintains the Anticancer Activity of Axitinib
by: Ying Fu, et al.
Published: (2022-04-01)

Cutaneous ulcers in association with sprue‐like enteropathy secondary to Losartan
by: Francis Essien, et al.
Published: (2021-08-01)

Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials
by: Rodolfo Pedro Rothlin, et al.
Published: (2021-03-01)

Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model
by: Wende Li, et al.
Published: (2021-03-01)

COVIDMED – An early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients
by: Daniel Freilich, et al.
Published: (2022-10-01)

Efficacy and safety of losartan in childhood immunoglobulin A nephropathy: a prospective multicenter study
by: Hyesun Hyun, et al.
Published: (2023-12-01)

Nephroprotective effect of vitamin E added to angiotensin receptor blocker in patients with diabetic nephropathy
by: Abdulrazzaq Alkaaby, et al.
Published: (2021-12-01)

Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate
by: Dragović Tamara, et al.
Published: (2010-01-01)

The effects of blocking angiotensin receptors on early stages of diabetic nephropathy
by: Alaleh Gheissari, et al.
Published: (2012-01-01)

The Effect of Crocin and Losartan on Biochemical Parameters and Oxidative Stress Markers in Diabetic Nephropathy Rats Model
by: Yaser Mohammadi, et al.
Published: (2022-07-01)

The effect of crocin and losartan on TGF-β gene expression and histopathology of kidney tissue in a rat model of diabetic nephropathy
by: Yaser Mohammadi, et al.
Published: (2023-03-01)

Transforming growth factor-β in diabetic nephropathy
by: Karima Y. Ahmed, et al.
Published: (2013-01-01)

Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy
by: Dan-Dan Qiu, et al.
Published: (2018-01-01)

Losartan to slow the progression of mild-to-moderate Alzheimer’s disease through angiotensin targeting: the RADAR RCT
by: Patrick G Kehoe, et al.
Published: (2021-11-01)

Angiotensin receptor blockers in nephroprotection at patients with diabetes mellitus: focus on losartan
by: Ol'ga Konstantinovna Vikulova, et al.
Published: (2009-09-01)

Therapeutic approaches to slowing the progression of diabetic nephropathy – is less best?
by: Eva Vivian, et al.
Published: (2013-03-01)

Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan
by: Antônio Carlos Avanza Jr, et al.
Published: (2000-02-01)

Novel Insights into the Antagonistic Effects of Losartan against Angiotensin II/AGTR1 Signaling in Glioblastoma Cells
by: Salvatore Panza, et al.
Published: (2021-09-01)

The role of angiotensin receptor blocker (losartan) on decreasing fibrotic process of corpora cavernosa in priapism model of wistar rats [version 3; peer review: 1 approved, 2 approved with reservations]
by: Rangga Adhazi Ksatriapraja, et al.
Published: (2024-02-01)

The role of angiotensin receptor blocker (losartan) on decreasing fibrotic process of corpora cavernosa in priapism model of wistar rats [version 2; peer review: 1 approved, 2 approved with reservations]
by: Rangga Adhazi Ksatriapraja, et al.
Published: (2023-05-01)

The effect of losartan on angiotensin II-induced cell proliferation in a rat aorta smooth muscle cell line
by: Natália Tambelline, et al.
Published: (2012-04-01)

Tetrahydrocurcumin Add‐On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury
by: Mahyar Khazaeli, et al.
Published: (2023-04-01)

Skin Reactions with Losartan and Enalapril in Cardiac Patients
by: Fariba Iraji, et al.
Published: (2012-03-01)

Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
by: Ram CV
Published: (2011-05-01)

EFFECT OF ANGIOTENSIN-II RECEPTOR ANTAGONIST LOSARTAN AND ITS COMBINATION WITH DIURETICS ON MYOCARDIAL MORPHO-FUNCTIONAL CONDITIONS IN HYPERTENSIVE PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY
by: S. N. Tolpygina, et al.
Published: (2016-01-01)

Determining the Effects of Morphine, Heroin, and Losartan and the Interaction of each on Losartan in Water Homeostasis Mechanisms by the Kidney in Adult Male Rabbits
by: F Foroohi, et al.
Published: (2015-04-01)

An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19
by: Charles D. Bengtson, et al.
Published: (2021-02-01)

Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Contrast-Induced Nephropathy
by: Letian Zhou, et al.
Published: (2014-03-01)

Efficacy and Safety of Renin-Angiotensin Aldosterone System Inhibitor in Patients with IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials
by: Yu ZHAO, et al.
Published: (2019-09-01)

Effects of the DASH diet and losartan on serum urate among adults with hypertension: Results of a randomized trial
by: Noelle Castilla‐Ojo, et al.
Published: (2023-10-01)

ACE insertion/deletion (I/D) polymorphism and diabetic nephropathy
by: Zohreh Rahimi
Published: (2012-10-01)

The effect of angiotensin 1-7 and losartan on renal ischemic/reperfusion injury in male rats
by: Tahereh Safari, et al.
Published: (2019-01-01)

Angiotensin II type 1 receptor blockers prevent aortic arterial stiffness in elderly patients with hypertension
by: Mo-Li Zhu, et al.
Published: (2019-10-01)

From the choice of antihypertensive drug to the choice of fixed combinations of antihypertensive drugs: a paradigm shift
by: O D Ostroumova, et al.
Published: (2015-12-01)

Losartan inhibits hyposmotic-induced increase of IKs current and shortening of action potential duration in guinea pig atrial myocytes
by: Jie Gao, et al.
Published: (2019-12-01)

A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients
by: Gustavo Castaño, et al.
Published: (2003-01-01)